{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-034692","form_type":"8-K","ticker":"NOTV","cik":"0000720154","company_name":"Inotiv, Inc.","filed_at":"2023-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.818022+00:00","generated_at":"2026-06-09T21:18:24.600084+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Inotiv appoints Terry Coelho to board, replacing Richard Johnson effective Oct 16, 2023","bullets":["Richard A. Johnson resigned as director; Terry Coelho appointed as Class II director.","Coelho also joins Compensation, Audit, and chairs Nominating/Corporate Governance committees.","Coelho is CFO of Gamida Cell; previously led CinCor Pharma's $190M IPO and its sale to AstraZeneca.","Director annual cash retainer $55,000; committee chairs/members receive additional retainers.","Coelho granted 12,911 restricted stock units as initial equity award."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-034692","json":"https://secwatch.observer/filing/0001628280-23-034692.json","markdown":"https://secwatch.observer/filing/0001628280-23-034692.md","text":"https://secwatch.observer/filing/0001628280-23-034692.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/720154/000162828023034692/0001628280-23-034692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/720154/000162828023034692/notv-20231016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:18:24.600084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"700a64e08b","claim":"Terry Coelho was appointed as Director at Inotiv, Inc..","evidence_excerpt":"The Board has appointed Terry Coelho to the Board, effective October 16, 2023, to serve as a Class II director of the Company for a term ending at the Annual Meeting of Shareholders in 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/720154/000162828023034692/0001628280-23-034692-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b82c893682","claim":"Richard A. Johnson resigned as Director at Inotiv, Inc..","evidence_excerpt":"Richard A. Johnson, Ph.D. previously tendered his resignation as a director of the Company, to be effective automatically upon notice to Dr. Johnson from the Company that the Board of Directors (the \"Board\") is prepared to elect an approved director as provided in the Shareholders Agreement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/720154/000162828023034692/0001628280-23-034692-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}